Serum IgG2 levels are specifically associated with whole-body insulin-mediated glucose disposal in non-diabetic offspring of type 2 diabetic individuals. a cross-sectional study
.Preclinical studies suggested that IgG2c isotype may specifically impair skeletal muscle insulin
sensitivity in mice. In this study we investigated the association between serum levels of the four IgG
subclasses and insulin sensitivity in non-diabetic individuals. Total IgG, IgG1, IgG2, IgG3 and IgG4
levels were measured in 262 subjects. Whole-body insulin sensitivity was assessed by euglycemic
hyperinsulinemic clamp. IgG2 levels were positively correlated with BMI, waist circumference, 2-h postload
glucose levels and complement C3. Serum IgG2, but not IgG1, IgG3 and IgG4 levels were negatively
correlated with whole-body insulin sensitivity (r = −0.17; P = 0.003) and muscle insulin sensitivity index
(r = −0.16; P = 0.03) after adjustment for age and gender. No significant correlation was found between
IgG2 levels and hepatic insulin resistance assessed by HOMA-IR and liver IR index. In a multivariable
regression analysis including variables known to affect insulin sensitivity such as age, gender, BMI,
smoking, lipids, inflammatory markers, fasting and 2-h post-load glucose levels, IgG2 levels were
independently associated with insulin-stimulated glucose disposal (β = −0.115, 95% CI: −0.541 to
−0.024; P = 0.03). These data demonstrate the independent association between higher levels of IgG2
and decreased whole-body insulin sensitivity, thus confirming in humans the animal-based evidence
indicating the pathogenic role of IgG2 in insulin resistance